THEREMIA is a French deeptech company specializing in precision medicine. It has developed an artificial intelligence platform allowing medical treatments to be personalized according to the specificities of each patient. By adjusting parameters such as frequency, dosage and drug formulation, Theremia seeks to improve the effectiveness of treatments while reducing side effects, a central objective for strengthening patient adherence.
A crucial issue for medical care
Standard treatments, often developed for typical patient profiles, show significant limits. Around 60% of patients abandon their treatment due to side effects or insufficient results. Theremia addresses this issue by integrating multi-scale AI-based models that adapt medications to the pathophysiological particularities of patients. This personalization helps minimize risks and maximize the effectiveness of treatments, thereby increasing the likelihood that patients will adhere to their care protocol.
A robust scientific approach
Theremia bases its model on validated methods combining data science, artificial intelligence and pharmacology. The startup works closely with practitioners specializing in various pathologies, particularly those of the central nervous system, such as Parkinson’s, Alzheimer’s, depression and multiple sclerosis. These partnerships make it possible to continually refine the algorithms and ensure that the treatments offered are scientifically coherent and adapted to the specificities of each disease.
Impact for drug developers
In a context where pharmaceutical companies need to demonstrate the effectiveness of their treatments for specific patient subgroups, Theremia offers a solution that facilitates the collection of real-world data (RWD). By making it possible to prove the impact of treatments on targeted groups, Theremia supports companies in their “Value-Based Healthcare” approach and helps to strengthen the confidence of regulators, payers and patients.
A complementary management team
Theremia is directed by Iris Maréchal, former consultant at BCG specializing in public health and mathematics, and by Chloé Geoffroy, pharmacist, engineer and doctor in neuroscience. Together, they lead a team of around ten employees, mainly from scientific and technological fields, working on projects focused on the optimization of treatments using AI.
Fundraising to accelerate development
Theremia recently raised 3 million euros in seed funding led by Eurazeo and Salica Investments, with the support of Entrepreneur First, BPIFrance, and renowned business angels. This funding aims to strengthen the scientific team and develop partnerships with medical institutes to perfect the treatment personalization algorithm. Theremia therefore intends to accelerate its deployment in Europe and become a key player in precision medicine.
To contact us, we have prepared a short form for you to properly manage your request and be able to send it in complete confidentiality. Click here to access it 
The latest articles by LA REDACTION DE FRENCHWEB.FR (see all)
